• Users Online: 835
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
ORIGINAL ARTICLE
Year : 2019  |  Volume : 47  |  Issue : 2  |  Page : 80-86

Effects of berberine on high-fat/high-sucrose-induced nonalcoholic steatohepatitis in experimental rats


Medical Biochemistry Department, Tanta University, Tanta, Egypt

Date of Submission01-Jun-2018
Date of Acceptance01-Sep-2019
Date of Web Publication18-May-2020

Correspondence Address:
Elrefaei Eman
BSc of Medicine and Surgery Faculty of Medicine, Tanta University, Elgarbia, 3151
Egypt
Login to access the Email id


DOI: 10.4103/tmj.tmj_15_18

Rights and Permissions
  Abstract 


Background Nonalcoholic steatohepatitis (NASH) is the most common chronic liver disease in the world, characterized by hepatic steatosis, inflammation, hepatocyte injury with or without fibrogenesis, which might lead to cirrhosis. Berberine (BBR) is a natural isoquinoline alkaloid with very impressive health benefits.
Aim The aim of the study is to evaluate the protective effect of BBR in experimental NASH induced by high-fat/high-sucrose diet in male albino rats.
Materials and methods Sixty male albino rats were divided randomly into four equal groups: group I (normal control group), group II (BBR-treated control group), group III (NASH group), and group IV (BBR-treated NASH group). Levels of peroxisome proliferator gamma receptor coactivator one alpha (PGC-1α) in hepatic nuclear extract were measured by enzyme-linked immunosorbent assay, while the activity of cytosolic glycerol-3-phosphate dehydrogenase 1 in the liver tissue homogenate, liver enzymes, lipid profile, and plasma ferric reducing/antioxidant power were measured spectrophotometrically.
Results There was a statistically significant decrease of hepatic PGC-1α, plasma ferric reducing/antioxidant power, serum high-density lipoprotein-cholesterol along with a significant increase in the activity of glycerol-3-phosphate dehydrogenase 1, liver enzymes as well as hyperlipidemia in the NASH group were compared with both normal control and BBR-treated control groups. These pathological disturbances were significantly ameliorated by BBR supplementation.
Conclusion The present study provided unequivocal evidence that disturbed hepatic PGC-1α and altered redox status acted as major contributing factors for the pathogenesis of high-fat/high-sucrose-induced NASH in rats. It also shed some light on the potential therapeutic value of BBR in NASH, partly accredited to its hypolipidemic and antioxidant effects, in addition to upregulating the levels of PGC-1α in hepatic nuclear extracts.

Keywords: berberine, lipin-1, oxidative stress


How to cite this article:
Eman E, Hemat E, Hanaa H, Safwat Q. Effects of berberine on high-fat/high-sucrose-induced nonalcoholic steatohepatitis in experimental rats. Tanta Med J 2019;47:80-6

How to cite this URL:
Eman E, Hemat E, Hanaa H, Safwat Q. Effects of berberine on high-fat/high-sucrose-induced nonalcoholic steatohepatitis in experimental rats. Tanta Med J [serial online] 2019 [cited 2020 Sep 23];47:80-6. Available from: http://www.tdj.eg.net/text.asp?2019/47/2/80/284493




  Introduction Top


Nonalcoholic steatohepatitis (NASH) represents an advanced stage of fatty liver disease developed in the absence of alcohol abuse [1]. NASH is the most common chronic liver disease in the Western world, it is primarily a disease of the obese and the prevalence of simple steatosis in obese patients reaches 60%, among those, 20–25% will develop NASH [2]. The disease is characterized by fat accumulation in the liver which results from an imbalance among hepatic lipid intake, synthesis, degradation, and secretion [3]. Patients with simple steatosis progress to NASH according to the multihit theory, liver steatosis sensitizes hepatocytes to other hits, leading to hepatocyte damage, inflammation, and fibrosis. These insults may be increased in oxidative stress and lipid peroxidation, mitochondrial dysfunction, and cytokine/adipokine imbalance [4],[5].

The transcriptional coactivator peroxisome proliferator gamma receptor coactivator one alpha (PGC-1α) regulates many metabolic programs, especially those related to oxidative metabolism. First identified as a coactivator of peroxisomal prolifirator activator receptor gamma (PPARγ) in brown fat-mediated thermogenesis, PGC-1α is now known to interact with many nuclear receptors and other transcription factors outside of this family [6]. In the liver, PGC-1α is strongly induced in fasting and turns on the gene programs of gluconeogenesis, heme biosynthesis, and fatty acid oxidation. This occurs through coactivation of hepatic estrogen-related receptor α, nuclear respiratory factor 1, nuclear respiratory factor 2, PPARα, hepatic nuclear factor-4α, and forkhead box class O1 [7].

The term oxidative stress refers to the outcome of oxidative damage to biologically relevant macromolecules such as nucleic acids, proteins, lipids, and carbohydrates. Oxidative stress occurs when oxidative stress-related molecules, generated in the extracellular environment or within the cell, exceed intracellular antioxidant defenses [8].

Oxidative stress represents a key feature of NASH [9], where activated neutrophils, macrophages, and Kupffer cells are the major source of reactive oxygen species during inflammation.

Glycerol-3-phosphate dehydrogenase (GPDH) is an enzyme that catalyzes the reversible redox conversion of dihydroxyacetone phosphate to glycerol-3-phosphate. It serves as a major link between carbohydrate metabolism and lipid metabolism [10].

Berberine (BBR) is a proto-BBR alkaloid, and its derivatives exhibit a wide spectrum of pharmacological activities. It has been used in traditional Chinese medicine. BBR along with its derivatives or in combination with other pharmaceutically active compounds or in the form of formulations has applications in various therapeutic areas such as cancer, inflammation, diabetes, depression, hypertension, and various infectious areas [11]. So, it was aimed to evaluate the protective effect of BBR in experimental NASH induced by a high-fat/high-sucrose diet in male albino rats.


  Materials and methods Top


Animals

This study was carried out on 60 male albino rats weighing 200±14 g. During the whole period of the study (12 weeks), animals were housed in wire mesh cages and were allowed free access to water and to either a standard rat chew or high-fat/high-sucrose diet and 10% sucrose in their drinking water. They were kept under constant environmental conditions (temperature 23±2°C and 12 h dark light cycle). Care of the animals and the experimental procedures were performed in the Medical Biochemistry Department, Faculty of Medicine, Tanta University, Egypt, in accordance with guidelines of the ethics committee of Faculty of Medicine, Tanta University, Egypt (Approval code 31085/08/16).

Chemicals

BBR (≥95% purity, CAS NO: 633-65-8) and most other chemicals were purchased from Sigma-Aldrich Chemicals (St Louis, Missouri, USA).

Induction of nonalcoholic steatohepatitis

NASH was induced in the third and fourth groups by a combination of feeding high-fat/high-sucrose diet plus 10% sucrose in their drinking water for 6 weeks. The high-fat/high-sucrose diet contained 20% of energy as protein, 35% as carbohydrates (18% sucrose, 10% maltodextrin, and 7% starch) and 45% as lipids according to Lomba et al. [12]. Subsequently, the fourth group was administered oral BBR at a dose of 200 mg/kg/day for another 6 weeks. Every 5 days, ingredients for diets were mixed, formed into dough with water, rolled into pellets, and stored at −20°C until use.

Experimental design

After being acclimatized for 1 week, the studied animals were divided randomly into four equal groups as follows:
  1. Group I (control group): this group included 15 rats which received a standard diet for 12 weeks.
  2. Group II (BBR-treated control group): this group included 15 rats which received a standard diet for 6 weeks followed by oral supplementation of BBR (200 mg/kg/day) for another 6 weeks [13].
  3. Group III (NASH group): this group included 15 rats. NASH was induced by feeding rats a high-fat/high-sucrose diet in addition to 10% sucrose in their drinking water for 6 weeks [12].
  4. Group IV (BBR-treated NASH group): this group included 15 rats. NASH was induced by feeding rats a high-fat/high-sucrose diet in addition to 10% sucrose in their drinking water for 6 weeks followed by oral supplementation of BBR (200 mg/kg/day) for another 6 weeks [13].


Collection and preparation of samples

At the end of the experiment, all rats were weighed and fasted overnight. Then, they were sacrificed by cervical decapitation. Blood samples were collected immediately; 1 ml of blood was collected on EDTA-coated tubes to obtain plasma, and the other part of blood was collected on plain tubes to obtain serum. All samples were separated by centrifugation at 3000 rpm for 15 min. The abdomen of the rats was dissected, and the livers were excised, washed by ice-cold saline. One part was homogenized in four volumes of ice-cold 50 mmol/l tri(hydroxymethyl)-aminomethane (Tris) buffer (pH 7.5) containing 1 mmol/l EDTA, 1 mM β-mercaptoethanol, and 0.5% Triton X-100, then centrifugated, and the final supernatant fraction was collected as the source of G3PDH enzyme. Another part was used for the preparation of nucleic acid-free nuclear proteins, by using EpiQuiK nuclear extraction kit (catalog number: #OP-0022), (Epigentek Co., Farmingdale, New York, USA).

Biochemical analysis

Assessment of liver enzymes: serum alanine aminotransferase and aspartate aminotransferase activities were measured by commercially available reagent kit obtained from Spectrum Diagnostic Co. (Cairo, Egypt) According to the method of Reitman and Frankel [14].

Assessment of lipid profile: serum triglycerides [15], total cholesterol [16], and high-density lipoprotein-cholesterol (HDL-C) [17] were estimated using enzymatic colorimetric methods (Spectrum Diagnostic Co.). Low-density lipoprotein-cholesterol (LDL-C) was calculated by Friedewald’s formula [18].

Assessment of antioxidant capacity of plasma: the ferric reducing/antioxidant power (FRAP) method was used to determine the total antioxidant capacity level of plasma. This depends on the reduction of ferric tripyridyltriazine complex to ferrous tripyridyltriazine by a reductant at low pH according to Benzie and Strain [19].

Assessment of PGC-1α level in hepatic nuclear extract: PGC-1α level in hepatic nuclear extract was determined by enzyme-linked immunosorbent assay kit purchased from Sun Red Biotechnology Co. (Shanghai, China), according to the instructions of the manufacturer.

Assessment of G3PDH activity: G3PDH activity was measured according to the method of Kozak and Jensen [20].

Statistical analysis

All results were expressed as means±SD. Differences between groups were assessed by one-way analysis of variance, followed by a post-hoc multiple comparison test. The association between the parameters was determined using Pearson’s correlation coefficient. A P value less than 0.05 was considered statistically significant. Statistical analysis was performed using the SPSS, version 20.0 statistical software package (SPSS Inc., Chicago, Illinois, USA).


  Results Top


[Table 1] summarized the comparative statistics of the studied parameters between all groups. Using the multiple comparison test (Tukey’s test), there were statistically significant increases in body weight values in the high-fat/high-sucrose-fed animals (groups III and IV) as compared with both standard diet-fed control groups (groups I and II). At the endpoint of the experiment (12th week), there was a statistically significant difference among the studied groups. There was a statistically significant decrease of hepatic PGC-1α, plasma FRAP, serum HDL-C along with a significant increase in the activity of GPDH1, liver enzymes as well as serum levels of total cholesterol (TC), triacyl glycerol (TAG), and LDL-C in the NASH group compared with both normal control and BBR-treated control groups. In addition, BBR administration resulted in an increase of hepatic PGC-1α, plasma FRAP, and serum HDL-C along with a significant decrease in the activity of GPDH1, liver enzymes as well as serum levels of TC, TAG, and LDL-C in BBR-treated NASH group compared with the NASH group ([Figure 1]).
Table 1 Comparative statistics of the studied parameters between all groups

Click here to view
Figure 1 Photomicrograph representation of the liver from the normal control group showing normal liver tissue; hepatocytes are normal polygonal cells with a single central nucleus, no steatosis, and no inflammatory infiltrate. Photomicrograph representation of the liver from the berberine-treated control group showing normal liver tissue; hepatocytes are normal polygonal cells with a single central nucleus, no steatosis, and no inflammatory infiltrate. Photomicrograph representation of nonalcoholic steatohepatitis (NASH) showing macrovesicular steatosis, ballooned hepatocytes, and lobular inflammation (H&E, ×200).

Click here to view



  Discussion Top


The present study depicted that treatment of NASH group with BBR resulted in a significant decrease in the levels of liver enzymes (alanine aminotransferase, aspartate aminotransferase) along with amelioration of these histopathological changes (as evidenced by a decreased number of fat vacuoles as well as decreased necrosis and inflammatory foci) compared with the untreated NASH group, claiming a hepatoprotective effect of BBR. Of relevance to this study, Xing et al. [21] demonstrated that the intragastric administration of BBR has been demonstrated to partially reverse the macrovesicular steatosis and inflammatory cell infiltration of portal areas and within hepatic lobules induced by a high-fat diet. Additionally, Guo et al. [22] reported that BBR improves aspects of NAFLD through ameliorating hepatic steatosis and suppressing the proinflammatory responses in primary hepatocytes of mice with diet-induced obesity.

Notably, in the current study daily oral supplementation with BBR for 6 weeks after NASH induction had a hypolipidemic action as evidenced by significantly decreased serum triacylglycerols, total cholesterol, and LDL levels as well as increased HDL levels as compared with the untreated NASH group.

This finding is not without precedence, having been previously noted by Zhao et al. [23] who provided evidence that BBR exerted a therapeutic effect on hepatic steatosis by inhibiting hepatic lipogenesis and comprehensively regulating the lipid metabolism. Likewise, BBR was shown to decrease hepatic steatosis in high-fat diet-fed rats [24],[25],[26], and in a randomized, placebo-controlled trial in patients with NAFLD [27], suggesting an essential role of liver in BBR-mediated lipid homeostasis.

Recently, it has been shown that BBR-induced improvement of hyperlipidemia and fatty liver in obese animals is mediated by the direct and indirect activation of AMP-activated protein kinase (AMPK), in peripheral tissues, notably the liver and muscle, and adipose tissue [28]. Once activated, AMPK is capable of suppressing lipogenesis through phosphorylating and inactivating the lipogenic enzyme acetyl-CoA carboxylase. In addition, a decrease in the production of malonyl-CoA due to AMPK inhibition of ACC brings about an increase in fatty acid oxidation via releasing the inhibitory effect of malonyl-CoA on carnitine palmitoyl transferase 1 [29],[30].

Alternatively, these effects could be also attributed to the observation that BBR modulates the gut microbiota through enriching short-chain fatty acid-producing bacteria and reducing the microbial diversity, which inhibits dietary polysaccharide degradation and decreases additional calorie intake in the gut, which may have beneficial effects to the host’s metabolic status [31].

The current study displayed that PGC-1α protein levels in hepatic nuclear extracts were significantly diminished in the high-fat/high-sucrose-induced NASH group compared with both normal control and BBR-treated control groups, thus proposing a possible role of altered activity of PGC-1α in the pathogenesis of high-fat/high-sucrose-induced NASH.

This finding came in accordance with that of Aharoni-Simon et al. [32], who reported a significant reduction in PGC-1α protein levels in steatotic livers of a choline-deficient, ethionine-supplemented-fed mice in comparison to control mice. Consequently, they further confirmed this attenuated PGC-1α activity by chromatin immunoprecipitation analysis, which demonstrated decreased interaction of PGC-1α with promoters of its potential target genes such as those regulating mitochondrial biogenesis and the gluconeogenic gene phosphoenolpyruvate carboxykinase in mice fed the choline-deficient, ethionine-supplemented diet.

In this context, Morris et al. [33] provided evidence that PGC-1α overexpression in primary hepatocytes produced an increase in the markers of mitochondrial content and function (citrate synthase, mitochondrial DNA, and electron transport system complex proteins), and an increase in fatty acid oxidation, which was accompanied by reduced TAG storage and TAG secretion compared with the control. Also, they stated that PGC-1α-overexpressing hepatocytes were protected from excess TAG accumulation following overnight lipid treatment. Moreover, PGC-1α overexpression in hepatocytes lowered the expression of genes critical to VLDL assembly and secretion ‘apolipoprotein B and microsomal triglyceride transfer protein’ [32].

Furthermore, the present study revealed that oral supplementation of BBR efficiently caused a significant increase of PGC-1α levels in hepatic nuclear extracts of BBR-treated NASH group as compared with the untreated high-fat/high-sucrose-induced NASH.

SIRT1 has emerged as a key regulator of mammalian metabolism, and has been shown to deacetylate and activate PGC-1α [34]. One hypothesis to explain the effect of BBR on hepatic PGC-1α levels might be based on the study by Sun et al.[35], who has defined BBR as an activator of SIRT1 by using liver-specific SIRT1 knockout mice and SIRT1-/-hepatocytes, thus implying an essential role of SIRT1 in mediating BBR’s induction of autophagy flux and reduction of hepatic fat storage.

This notion was further confirmed by earlier studies indicating that BBR protects against high-fat-diet-induced dysfunction in the muscle mitochondria by inducing (SIRT1)-dependent mitochondrial biogenesis [36].

The data obtained from the present study clearly indicated that the high-fat/high-sucrose-fed rats exhibited a highly significant increase in hepatic cytosolic enzyme GPDH1 activity compared with both the normal control and BBR-treated control rats. This finding is biologically plausible as enhanced cytosolic GPDH1 activity leads to an increase in glycerol-3-phosphate production which serves as the direct precursor for TAG synthesis [37]. Consequently, its abundance and augmented activity can easily contribute to an enhanced TAG accumulation in the liver and epididymal adipose tissue of high-fat-diet-fed rats [38],[39].Furthermore, this study has shown that treatment with BBR resulted in a significant decrease of the hepatic GPDH1 activity; importantly this attenuation was significant in relation to the untreated high-fat/high-sucrose-fed rats. In agreement with our finding, Ragab et al. [40] have also found that BBR administration returned the augmented GPDH1 activity in hepatic tissues of high-fat/high-sucrose-fed rats to the control levels.

The present study has reported that NASH was associated with altered redox status as judged by a significant reduction of plasma FRAP levels compared with both normal control and BBR-treated control groups.

This finding correlates well with the earlier studies that have shown that HFD disturbed redox status through antioxidant depletion, thus contributing to NAFLD development [41],[42]. Nevertheless, the current study displayed that BBR administration to the high-fat/high-sucrose-induced NASH group resulted in augmentation of their plasma antioxidant capacity as shown by elevated plasma FRAP levels as compared with the untreated NASH group, thus providing an experimental evidence that BBR treatment was able to reduce oxidative stress and to limit the development of NASH.

Several lines of in-vitro and in-vivo evidence corroborate this notion. Zhang et al. [43] have demonstrated that BBR attenuated ethanol-induced oxidative stress in the liver by reducing hepatic lipid peroxidation, glutathione exhaust, and mitochondrial oxidative damage. Meanwhile, Liu et al. [44] proved that BBR possessed the anti-oxidative effects as shown by the reduced plasma malondialdehyde level and increased superoxide dismutase activity significantly, thus protecting against the oxidative stress-related damage following the high-glucose high-fat load.


  Conclusion Top


In conclusion, the present study provided unequivocal evidence that disturbed hepatic PGC-1α signaling and the altered redox status acted as major contributing factors for the pathogenesis of high-fat/high-sucrose-induced NASH in experimental rats. It also shed some light on the potential therapeutic value of BBR in NASH; which might be partly accredited to its hypolipidemic and antioxidant effects. Moreover, BBR was found to significantly upregulate the levels of PGC-1α in hepatic nuclear extracts of BBR-treated NASH group as compared with the untreated NASH group. However, further studies are warranted to justify its therapeutic efficacy before nominating it as a potential drug candidate for preventing or treating NASH and related disorders in humans.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Abd El-Kader SM, El-Den Ashmawy EMS. Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol 2015; 7:846–858.  Back to cited text no. 1
    
2.
Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21:11053–11076.  Back to cited text no. 2
    
3.
Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimt Biophy Acta 2015; 1852:1765–1778.  Back to cited text no. 3
    
4.
Baran B, Akyüz F. Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? World J Gastroenterol 2014; 20:14219–14229.  Back to cited text no. 4
    
5.
Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiology 2016; 7:211–217.  Back to cited text no. 5
    
6.
Kim J, Fernand VE, Henagan TM, Shin J. Regulation of brown and white adipocyte transcriptome by the transcriptional coactivator NT-PGC-1α. PloS One 2016; 11:159–190.  Back to cited text no. 6
    
7.
Lustig Y, Ruas JL, Estall JL, Lo JC, Devarakonda S. Separation of the gluconeogenic and mitochondrial functions of PGC-1α through S6 kinase. Genes Dev 2011; 25:1232–1244.  Back to cited text no. 7
    
8.
Rahal A, Kumar A, Singh V, Yadav B, Tiwari R, Chakraborty S et al. Oxidative stress, prooxidants, and antioxidants: the interplay. BioMed Res Int 2014; 19:377–391.  Back to cited text no. 8
    
9.
Esrefoglu M. Oxidative stress and benefits of antioxidant agents in acute and chronic hepatitis. Hepat Mon 2012 12:160–167.  Back to cited text no. 9
    
10.
He Y, Meng X, Fan Q, Sun X, Xu Z, Song R. Cloning and characterization of two novel chloroplastic glycerol-3-phosphate dehydrogenases from Dunaliella viridis. Plant Mol Biol 2009; 71:193–205.  Back to cited text no. 10
    
11.
Singh IP, Mahajan S. Berberine and its derivatives: a patent review (2009-2012). Expert Opin Ther Pat 2013; 23:215–231.  Back to cited text no. 11
    
12.
Lomba A, Milagro FI, Garcia-Diaz DF, Marti A, Campion J, Martinez JA. Obesity induced by a pair-fed high fat sucrose diet: methylation and expression pattern of genes related to energy homeostasis. Lipids Health Dis 2010; 9:60–70.  Back to cited text no. 12
    
13.
Zhang Y, Chang X, Song X, Chen C, Chen H, Lu Z et al. Berberine reverses abnormal expression of L-type pyruvate kinase by DNA demethylation and histone acetylation in the livers of the non-alcoholic fatty disease rat. Int J Clin Exp Med 2015; 8:7535–7543.  Back to cited text no. 13
    
14.
Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28:56–63.  Back to cited text no. 14
    
15.
Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28:2077–2080.  Back to cited text no. 15
    
16.
Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20:470–475.  Back to cited text no. 16
    
17.
Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 1977; 55:767–772.  Back to cited text no. 17
    
18.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502.  Back to cited text no. 18
    
19.
Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of ‘antioxidant power’: the FRAP assay. Anal Biochem 1996; 239:70–76.  Back to cited text no. 19
    
20.
Kozak LP, Jensen JT. Genetic and developmental control of multiple forms of L-glycerol 3-phosphate dehydrogenase. J Biol Chem 1974; 249:7775–7781.  Back to cited text no. 20
    
21.
Xing LJ, Zhang L, Liu T, Hua YQ, Zheng PY, Ji G. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol 2011; 668:467–471.  Back to cited text no. 21
    
22.
Guo T, Woo SL, Guo X, Li H, Zheng J, Botchlett R et al. Berberine ameliorates hepatic steatosis and suppresses liver and adipose tissue inflammation in mice with diet-induced obesity. Sci Rep 2016; 6:22612.  Back to cited text no. 22
    
23.
Zhao L, Cang Z, Sun H, Nie X, Wang N, Lu Y. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. BMC Endocr Disord 2017; 17:13–23.  Back to cited text no. 23
    
24.
Yuan X, Wang J, Tang X, Li Y, Xia P, Gao X. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. J Transl Med 2015; 13:24–24.  Back to cited text no. 24
    
25.
Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PloS One 2011; 6:16556–16566.  Back to cited text no. 25
    
26.
Chang W, Chen L, Hatch GM. Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochem Cell Biol 2014; 93:479–486.  Back to cited text no. 26
    
27.
Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease. PloS One 2015; 10:13417–13428.  Back to cited text no. 27
    
28.
Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab 2009; 296:812–819.  Back to cited text no. 28
    
29.
Hardie DG. AMP-activated protein kinase—an energy sensor that regulates all aspects of cell function. Genes Dev 2011; 25:1895–1908.  Back to cited text no. 29
    
30.
Cao S, Zhou Y, Xu P, Wang Y, Yan J, Bin W et al. Berberine metabolites exhibit triglyceride-lowering effects via activation of AMP-activated protein kinase in Hep G2 cells. J Ethnopharmacol 2013; 149:576–582.  Back to cited text no. 30
    
31.
Zhang X, Zhao Y, Xu J, Xue Z, Zhang M, Pang X et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep 2015; 5:20–42.  Back to cited text no. 31
    
32.
Aharoni-Simon M, Hann-Obercyger M, Pen S, Madar Z, Tirosh O. Fatty liver is associated with impaired activity of PPARγ-coactivator 1α (PGC1α) and mitochondrial biogenesis in mice. Lab Investig 2011; 91:1018–1028.  Back to cited text no. 32
    
33.
Morris EM, Meers GM, Booth FW, Fritsche KL, Hardin CD, Thyfault JP et al. PGC-1α overexpression results in increased hepatic fatty acid oxidation with reduced triacylglycerol accumulation and secretion. Am J PhysiolGastrointest Liver Physiol 2012; 303:979–992.  Back to cited text no. 33
    
34.
Li Y, Xu S, Li J, Zheng L, Feng M, Wang X et al. SIRT1 facilitates hepatocellular carcinoma metastasis by promoting PGC-1α-mediated mitochondrial biogenesis. Oncotarget 2016; 7:292–300.  Back to cited text no. 34
    
35.
Sun H, Wang N, Cang Z, Zhu C, Zhao L, Nie X et al. Modulation of microbiota-gut-brain axis by berberine resulting in improved metabolic status in high-fat diet-fed rats. Obes Facts 2016; 9:365–378.  Back to cited text no. 35
    
36.
Gomes AP, Duarte FV, Nunes P, Hubbard BP, Teodoro JS, Varela AT et al. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochim Biophys Acta 2012; 1822:185–195.  Back to cited text no. 36
    
37.
Cahova M, Dankova H, Palenickova E, Papackova Z, Kazdova L. The opposite effects of high-sucrose and high-fat diet on fatty acid oxidation and very low density lipoprotein secretion in rat model of metabolic syndrome. J Nutr Metabol 2012; 12:10–21.  Back to cited text no. 37
    
38.
Xu SP, Mao XY, Cheng X, Chen B. Ameliorating effects of casein glycomacropeptide on obesity induced by high-fat diet in male Sprague-Dawley rats. Food Chem Toxicol 2013; 56:1–7.  Back to cited text no. 38
    
39.
Xu SP, Mao XY, Ren FZ, Che HL. Attenuating effect of casein glycomacropeptide on proliferation, differentiation, and lipid accumulation of in vitro Sprague-Dawley rat preadipocytes. J Dairy Sci 2011; 94:676–683.  Back to cited text no. 39
    
40.
Ragab SMM, Abd Elghaffar SK, El-Metwally TH, Badr G, Mahmoud MH, Omar HM. Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds. Lipids Health Dis 2015; 14:83–92.  Back to cited text no. 40
    
41.
Vial G, Dubouchaud H, Couturier K, Cottet-Rousselle C, Taleux N, Athias A et al. Effects of a high-fat diet on energy metabolism and ROS production in rat liver. J Hepatol 2011; 54:348–356.  Back to cited text no. 41
    
42.
Heinonen I, Rinne P, Ruohonen S, Ruohonen S, Ahotupa M, Savontaus E. The effects of equal caloric high fat and western diet on metabolic syndrome, oxidative stress and vascular endothelial function in mice. Acta Physiol 2014; 211:515–527.  Back to cited text no. 42
    
43.
Zhang P, Ma D, Wang Y, Zhang M, Qiang X, Liao M et al. Berberine protects liver from ethanol-induced oxidative stress and steatosis in mice. Food Chem Toxicol 2014; 74:225–232.  Back to cited text no. 43
    
44.
Liu C, Wang Z, Song Y, Wu D, Zheng X, Li P et al. Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. Biomed Res Int 2015; 15:313–323.  Back to cited text no. 44
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Materials and me...
Results
Discussion
Conclusion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed426    
    Printed24    
    Emailed0    
    PDF Downloaded41    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]